MENU
+Compare
IBRN
ETF ticker: NYSE ARCA
AS OF
Jul 17 closing price
Price
$23.21
Change
+$1.32 (+6.03%)
Net Assets
3.41M

IBRN stock forecast, quote, news & analysis

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U... Show more

Category: #Health
IBRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for IBRN with price predictions
Jul 18, 2025

IBRN in downward trend: 10-day moving average crossed below 50-day moving average on July 01, 2025

The 10-day moving average for IBRN crossed bearishly below the 50-day moving average on July 01, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

IBRN broke above its upper Bollinger Band on July 17, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IBRN entered a downward trend on July 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 39 cases where IBRN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 16, 2025. You may want to consider a long position or call options on IBRN as a result. In of 54 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IBRN just turned positive on July 17, 2025. Looking at past instances where IBRN's MACD turned positive, the stock continued to rise in of 29 cases over the following month. The odds of a continued upward trend are .

IBRN moved above its 50-day moving average on July 17, 2025 date and that indicates a change from a downward trend to an upward trend.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB), Intra-Cellular Therapies (NASDAQ:ITCI), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified.

Market Cap

The average market capitalization across the iShares Neuroscience and Healthcare ETF ETF is 3.16B. The market cap for tickers in the group ranges from 75.26M to 34.97B. ARGX holds the highest valuation in this group at 34.97B. The lowest valued company is ANRO at 75.26M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was 52%. For the same ETF, the average monthly price growth was 148%, and the average quarterly price growth was 136%. SLDB experienced the highest price growth at 21%, while SRPT experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was 94%. For the same stocks of the ETF, the average monthly volume growth was 133% and the average quarterly volume growth was 186%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 76
Price Growth Rating: 53
SMR Rating: 87
Profit Risk Rating: 86
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
IBRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com